文献速递血栓与止血淋巴瘤白血病

纤溶受损与血凝块强度增高是淋巴瘤患者血栓形成的潜在危险因素

Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

这项前瞻性队列研究纳入79例血液肿瘤患者,在治疗前和治疗开始后3个月检测纤溶动态。淋巴瘤患者纤溶受损,50%血凝块溶解时间较健康对照延长(P = .048),随访时血凝块强度较诊断时降低(P = .001);急性早幼粒细胞白血病和轻链淀粉样变患者则表现为纤溶亢进。

要点

  • 淋巴瘤患者纤溶受损,50%血凝块溶解时间较健康对照延长(P = .048)。
  • 淋巴瘤患者随访时血凝块强度较诊断时降低(P = .001)。
  • 急性早幼粒细胞白血病和轻链淀粉样变患者可见纤溶亢进。

核心结论

  • 淋巴瘤患者表现出纤溶受损和血凝块强度增高的征象,而急性早幼粒细胞白血病和轻链淀粉样变患者可见纤溶亢进。
  • 因此,研究血液肿瘤患者的纤溶状态可能具有诊断价值。

研究设计与样本

  • 前瞻性队列研究,共纳入79例血液肿瘤患者。
  • 在治疗前和治疗开始后3个月检测纤溶指标。

主要发现

  • 淋巴瘤患者50%血凝块溶解时间较健康对照延长(P = .048)。
  • 淋巴瘤患者随访时血凝块强度较诊断时降低(P = .001)。
  • 1例诊断时有明显出血的轻链淀粉样变患者表现为纤溶亢进,50%血凝块溶解时间缩短、α-2-抗纤溶酶活性和纤溶酶原活性降低、组织型纤溶酶原激活物和尿激酶型纤溶酶原激活物升高。
  • 1例急性早幼粒细胞白血病患者也表现为明显纤溶亢进,纤溶酶-抗纤溶酶复合物非常高,提示纤溶酶生成极强,血凝块形成无法测出,可能因纤溶极快所致。
  • 两例患者的纤溶在治疗后均恢复正常。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombosis and bleeding are significant contributors to morbidity and mortality in patients with hematological cancer, and the impact of altered fibrinolysis on bleeding and thrombosis risk is poorly understood. In this prospective cohort study, we investigated the dynamics of fibrinolysis in patients with hematological cancer. Fibrinolysis was investigated before treatment and 3 months after treatment initiation. A dynamic clot formation and lysis assay was performed beyond the measurement of plasminogen activator inhibitor 1, tissue- and urokinase-type plasminogen activators (tPA and uPA), plasmin-antiplasmin complexes (PAP), α-2-antiplasmin activity, and plasminogen activity. Clot initiation, clot propagation, and clot strength were assessed using rotational thromboelastometry. A total of 79 patients were enrolled. Patients with lymphoma displayed impaired fibrinolysis with prolonged 50% clot lysis time compared with healthy controls (P = .048). They also displayed decreased clot strength at follow-up compared with at diagnosis (P = .001). A patient with amyloid light-chain amyloidosis having overt bleeding at diagnosis displayed hyperfibrinolysis, indicated by a reduced 50% clot lysis time, α-2-antiplasmin activity, and plasminogen activity, and elevated tPA and uPA. A patient with acute promyelocytic leukemia also displayed marked hyperfibrinolysis with very high PAP, indicating extreme plasmin generation, and clot formation was not measurable, probably because of the extremely fast fibrinolysis. Fibrinolysis returned to normal after treatment in both patients. In conclusion, patients with lymphoma showed signs of impaired fibrinolysis and increased clot strength, whereas hyperfibrinolysis was seen in patients with acute promyelocytic leukemia and light-chain amyloidosis. Thus, investigating fibrinolysis in patients with hematological cancer could have diagnostic value.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bønløkke ST, Fenger-Eriksen C, Ommen HB, et al. Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma. Blood Adv. 2023. PMID: 37756519. doi:10.1182/bloodadvances.2023011379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。